Citations

Showing 10 of 108119 citations.

Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
Chanan‐Khan, Asher , Agarwal, Amit , Lebovic, Daniel, Darden, David E., Morris, Lura, Munasinghe, Wijith, Zhu, Ming , Enschede, Sari H., Humerickhouse, Rod, Touzeau, Cyrille , Roberts, Andrew W. , Facon, Thierry T.F. , Moreau, Philippe , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8580-8580

10.1200/jco.2015.33.15_suppl.8580 Get It

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.
Morice, William G. , Timm, Michael, Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Kapoor, Prashant , Kumar, Shaji , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Morice, William George , Dispenzieri, Angela , Buadi, Francis K. , Lin, Yi , Dingli, David , Leung, Nelson , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8577-8577

10.1200/jco.2015.33.15_suppl.8577 Get It

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
Kumar, Shaji , Vij, Ravi , Alzate, Stefanie, Morris, Lura, Dunbar, Martin, Zhu, Ming , Enschede, Sari H., Humerickhouse, Rod, Kaufman, Jonathan L. , Mıkhael, Joseph , Facon, Thierry T.F. , Moreau, Philippe , Amiot, Martine , Ross, Jeremy A. , Agarwal, Suresh K, Leverson, Joel D. , Touzeau, Cyrille

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8576-8576

10.1200/jco.2015.33.15_suppl.8576 Get It

Outcome comparison of allogeneic vs. autologous stem cell transplantation in transformed low grade lymphoid malignancies: A meta-analysis of comparative studies.
Yun, Seongseok , Vincelette, Nicole D. , Segar, Jennifer

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8566-8566

10.1200/jco.2015.33.15_suppl.8566 Get It

Early high-dose therapy and autologous stem-cell transplantation in angioimmunoblastic T-cell lymphoma: Outcome study using the National Cancer Data Base.
Karanam, Pawan Kumar, Al‐Hamadani, Mohammed , Parsons, Benjamin M. , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8560-8560

10.1200/jco.2015.33.15_suppl.8560 Get It

A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Forero‐Torres, Andres , Sher, Taimur , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Barr, Paul M. , Diefenbach, Catherine , Talpaz, Moshe , Phillips, Tycel

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8558-8558

10.1200/jco.2015.33.15_suppl.8558 Get It

Exercise patterns and quality of life among survivors of aggressive lymphoma.
Ferzoco, Raina Mahajan, Allmer, Cristine, Yost, Kathleen J. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Nowakowski, Grzegorz S. , Macon, William R. , Towns, Jessica N, Thompson, Carrie A. , Cerhan, James R. , Maurer, Matthew J. , Habermann, Thomas M. , Witzig, Thomas E. , Farooq, Umar , Link, Brian K.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8555-8555

10.1200/jco.2015.33.15_suppl.8555 Get It

Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE.
Nowakowski, Grzegorz S. , LaPlant, Betsy, Macon, William R. , Inwards, David J. , Micallef, Ivana N. , Wender, Donald B., Leonard, John P. , Gertz, Morie A. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8540-8540

10.1200/jco.2015.33.15_suppl.8540 Get It

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391)
Stewart, A. Keith, Mihaylov, Georgi , Rajnics, Péter , Suvorov, Aleksandr , Niesvizky, Rubén, Zojwalla, Naseem J., Palumbo, Antonio , Dimopoulos, Meletios Α. , Stewart, A. Keith, Rajkumar, S. Vincent , Masszi, Tamás , Oriol, Albert , Hájek, Roman , Rosiñol, Laura , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Miguel, Jesús F. San , Ludwig, Heinz , Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8525-8525

10.1200/jco.2015.33.15_suppl.8525 Get It

A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Sher, Taimur , Lebovic, Daniel, Zhou, Li , Pulini, Jennifer, Spear, Matthew A. , Forero‐Torres, Andres , Barr, Paul M. , Phillips, Tycel

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8607-TPS8607

10.1200/jco.2015.33.15_suppl.tps8607 Get It